Abbott said on November 18, 2025 it received a notice from the plan administrator of the Abbott Laboratories Stock Retirement Plan (U.S. Plan) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (P.R. Plan) pursuant to Section 101(i)(2)(E) of the Employee Retirement Income Security Act of 1974 regarding a blackout period.

1. 01

   Abbott said on November 18, 2025 it received a notice from the plan administrator of the Abbott Laboratories Stock Retirement Plan (U.S. Plan) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (P.R. Plan) pursuant to Section 101(i)(2)(E) of the Employee Retirement Income Security Act of 1974 regarding a blackout period.

2. 02

   The company cited changing the recordkeeper, changing the trustee for certain funds of the U.S. Plan, and changing the custodian for certain funds of the P.R. Plan as reasons for the blackout period. During the period, participants will be unable to change contribution rates, direct or diversify investments (including investments in Abbott common shares), or obtain a plan loan, withdrawal, or distribution.

3. 03

   Abbott said the blackout period is expected to begin on December 24, 2025 at 12 p.m. CST and is expected to end during the week of January 11, 2026. The actual beginning and ending dates of the blackout period may be obtained without charge during the blackout period and for 2 years after the ending date by submitting a request.

4. 04

   On November 21, 2025, the company sent a notice to its directors and executive officers informing them that during the blackout period, they are generally prohibited from directly or indirectly purchasing, selling, or otherwise transferring any equity security of Abbott. The company said these restrictions apply regardless of whether they participate in either of the Plans, and that the company's general insider trading policy prohibits trading from December 15, 2025 until after the Q4 earnings release.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.